Swiss health funds to raise premiums

16 February 2009

The Swiss health funds are expected to raise premiums in 2010 by between 9% and 20% to maintain the forecast level of reserves of 4% beyond the  end of this year.

The Santesuisse organization will negotiate with the funds to call for  reductions of cost growth from the current 4%-5% down to 2%-3%. Special  health cost control measures are therefore likely this year.

Meanwhile, the largest fund, the Helsana group, has posted a 2008 loss  of 218.0 million Swiss francs ($188.5 million) - its first deficit in  eight years - after problems in capital markets.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight